Clinical efficacy and safety of sirolimus in systemic lupus erythematosus: a real-world study and meta-analysis

Objective: To provide real-world data and summarize current clinical evidence on the efficacy and safety of sirolimus in active systemic lupus erythematosus (SLE) patients. Methods: This was a prospective real-world clinical study. Included SLE patients should have Systemic Lupus Erythematosus Disea...

Full description

Saved in:
Bibliographic Details
Published inTherapeutic advances in musculoskeletal disease Vol. 12; p. 1759720X20953336
Main Authors Peng, Liying, Wu, Chanyuan, Hong, Ruping, Sun, Yiduo, Qian, Junyan, Zhao, Jiuliang, Wang, Qian, Tian, Xinping, Wang, Yanhong, Li, Mengtao, Zeng, Xiaofeng
Format Journal Article
LanguageEnglish
Published London, England SAGE Publications 2020
SAGE PUBLICATIONS, INC
SAGE Publishing
Subjects
Effectiveness
Inhibitor drugs
Lupus
Meta-analysis
Original Research
Patient safety
Serology
mTOR inhibitor
treatment
lupus nephritis
systemic lupus erythematosus
thrombocytopenia
sirolimus
Online AccessGet full text

Cover

Abstract Objective: To provide real-world data and summarize current clinical evidence on the efficacy and safety of sirolimus in active systemic lupus erythematosus (SLE) patients. Methods: This was a prospective real-world clinical study. Included SLE patients should have Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) ⩾ 2. They were treated with sirolimus and followed up regularly. The SLEDAI-2K, Physician Global Assessment (PGA), serological activity indices, and remission of organ manifestations were evaluated. We also performed a meta-analysis to integrate current evidence of sirolimus in SLE. Results: A total of 49 patients were included in the final analysis. After treatment, the SLEDAI-2K (6.2 ± 3.1 versus 4.0 ± 3.4, p = 0.001) decreased significantly, and the prednisone dosage was tapered successfully (9.9 ± 8.8 mg/day versus 5.9 ± 4.0 mg/day, p = 0.002). Serological activity indices also improved [complement 3 (C3): 0.690 ± 0.209 g/l versus 0.884 ± 0.219 g/l, p < 0.001; complement 4: 0.105 ± 0.059 g/l versus 0.141 ± 0.069 g/l, p < 0.001; anti-dsDNA antibody, 200 ± 178 IU/ml versus 156 ± 163 IU/ml, p = 0.022]. The remission proportions of arthritis, skin rash, and thrombocytopenia were 100%, 88.8%, and 46.2%, respectively. A total of 41.2% of lupus nephritis (LN) patients achieved renal remission, but the average 24-h urine protein level was not significantly changed. Meta-analysis enrolled five studies with 149 patients included, and revealed similar results regarding the changes of SLEDAI-2K [−3.5 (−5.0, −2.1)], C3 [0.224 (0.136, 0.311) g/l] and daily dosage of prednisone [−12.7 (−19.9, −5.6) mg/day]. Conclusion: Sirolimus might be effective and tolerated in SLE. The role of sirolimus in LN requires further study.
AbstractList To provide real-world data and summarize current clinical evidence on the efficacy and safety of sirolimus in active systemic lupus erythematosus (SLE) patients. This was a prospective real-world clinical study. Included SLE patients should have Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) ⩾ 2. They were treated with sirolimus and followed up regularly. The SLEDAI-2K, Physician Global Assessment (PGA), serological activity indices, and remission of organ manifestations were evaluated. We also performed a meta-analysis to integrate current evidence of sirolimus in SLE. A total of 49 patients were included in the final analysis. After treatment, the SLEDAI-2K (6.2 ± 3.1 4.0 ± 3.4,  = 0.001) decreased significantly, and the prednisone dosage was tapered successfully (9.9 ± 8.8 mg/day 5.9 ± 4.0 mg/day,  = 0.002). Serological activity indices also improved [complement 3 (C3): 0.690 ± 0.209 g/l 0.884 ± 0.219 g/l,  < 0.001; complement 4: 0.105 ± 0.059 g/l 0.141 ± 0.069 g/l,  < 0.001; anti-dsDNA antibody, 200 ± 178 IU/ml 156 ± 163 IU/ml,  = 0.022]. The remission proportions of arthritis, skin rash, and thrombocytopenia were 100%, 88.8%, and 46.2%, respectively. A total of 41.2% of lupus nephritis (LN) patients achieved renal remission, but the average 24-h urine protein level was not significantly changed. Meta-analysis enrolled five studies with 149 patients included, and revealed similar results regarding the changes of SLEDAI-2K [-3.5 (-5.0, -2.1)], C3 [0.224 (0.136, 0.311) g/l] and daily dosage of prednisone [-12.7 (-19.9, -5.6) mg/day]. Sirolimus might be effective and tolerated in SLE. The role of sirolimus in LN requires further study.
Objective: To provide real-world data and summarize current clinical evidence on the efficacy and safety of sirolimus in active systemic lupus erythematosus (SLE) patients. Methods: This was a prospective real-world clinical study. Included SLE patients should have Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) ⩾ 2. They were treated with sirolimus and followed up regularly. The SLEDAI-2K, Physician Global Assessment (PGA), serological activity indices, and remission of organ manifestations were evaluated. We also performed a meta-analysis to integrate current evidence of sirolimus in SLE. Results: A total of 49 patients were included in the final analysis. After treatment, the SLEDAI-2K (6.2 ± 3.1 versus 4.0 ± 3.4, p  = 0.001) decreased significantly, and the prednisone dosage was tapered successfully (9.9 ± 8.8 mg/day versus 5.9 ± 4.0 mg/day, p  = 0.002). Serological activity indices also improved [complement 3 (C3): 0.690 ± 0.209 g/l versus 0.884 ± 0.219 g/l, p  < 0.001; complement 4: 0.105 ± 0.059 g/l versus 0.141 ± 0.069 g/l, p  < 0.001; anti-dsDNA antibody, 200 ± 178 IU/ml versus 156 ± 163 IU/ml, p  = 0.022]. The remission proportions of arthritis, skin rash, and thrombocytopenia were 100%, 88.8%, and 46.2%, respectively. A total of 41.2% of lupus nephritis (LN) patients achieved renal remission, but the average 24-h urine protein level was not significantly changed. Meta-analysis enrolled five studies with 149 patients included, and revealed similar results regarding the changes of SLEDAI-2K [−3.5 (−5.0, −2.1)], C3 [0.224 (0.136, 0.311) g/l] and daily dosage of prednisone [−12.7 (−19.9, −5.6) mg/day]. Conclusion: Sirolimus might be effective and tolerated in SLE. The role of sirolimus in LN requires further study.
To provide real-world data and summarize current clinical evidence on the efficacy and safety of sirolimus in active systemic lupus erythematosus (SLE) patients.OBJECTIVETo provide real-world data and summarize current clinical evidence on the efficacy and safety of sirolimus in active systemic lupus erythematosus (SLE) patients.This was a prospective real-world clinical study. Included SLE patients should have Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) ⩾ 2. They were treated with sirolimus and followed up regularly. The SLEDAI-2K, Physician Global Assessment (PGA), serological activity indices, and remission of organ manifestations were evaluated. We also performed a meta-analysis to integrate current evidence of sirolimus in SLE.METHODSThis was a prospective real-world clinical study. Included SLE patients should have Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) ⩾ 2. They were treated with sirolimus and followed up regularly. The SLEDAI-2K, Physician Global Assessment (PGA), serological activity indices, and remission of organ manifestations were evaluated. We also performed a meta-analysis to integrate current evidence of sirolimus in SLE.A total of 49 patients were included in the final analysis. After treatment, the SLEDAI-2K (6.2 ± 3.1 versus 4.0 ± 3.4, p = 0.001) decreased significantly, and the prednisone dosage was tapered successfully (9.9 ± 8.8 mg/day versus 5.9 ± 4.0 mg/day, p = 0.002). Serological activity indices also improved [complement 3 (C3): 0.690 ± 0.209 g/l versus 0.884 ± 0.219 g/l, p < 0.001; complement 4: 0.105 ± 0.059 g/l versus 0.141 ± 0.069 g/l, p < 0.001; anti-dsDNA antibody, 200 ± 178 IU/ml versus 156 ± 163 IU/ml, p = 0.022]. The remission proportions of arthritis, skin rash, and thrombocytopenia were 100%, 88.8%, and 46.2%, respectively. A total of 41.2% of lupus nephritis (LN) patients achieved renal remission, but the average 24-h urine protein level was not significantly changed. Meta-analysis enrolled five studies with 149 patients included, and revealed similar results regarding the changes of SLEDAI-2K [-3.5 (-5.0, -2.1)], C3 [0.224 (0.136, 0.311) g/l] and daily dosage of prednisone [-12.7 (-19.9, -5.6) mg/day].RESULTSA total of 49 patients were included in the final analysis. After treatment, the SLEDAI-2K (6.2 ± 3.1 versus 4.0 ± 3.4, p = 0.001) decreased significantly, and the prednisone dosage was tapered successfully (9.9 ± 8.8 mg/day versus 5.9 ± 4.0 mg/day, p = 0.002). Serological activity indices also improved [complement 3 (C3): 0.690 ± 0.209 g/l versus 0.884 ± 0.219 g/l, p < 0.001; complement 4: 0.105 ± 0.059 g/l versus 0.141 ± 0.069 g/l, p < 0.001; anti-dsDNA antibody, 200 ± 178 IU/ml versus 156 ± 163 IU/ml, p = 0.022]. The remission proportions of arthritis, skin rash, and thrombocytopenia were 100%, 88.8%, and 46.2%, respectively. A total of 41.2% of lupus nephritis (LN) patients achieved renal remission, but the average 24-h urine protein level was not significantly changed. Meta-analysis enrolled five studies with 149 patients included, and revealed similar results regarding the changes of SLEDAI-2K [-3.5 (-5.0, -2.1)], C3 [0.224 (0.136, 0.311) g/l] and daily dosage of prednisone [-12.7 (-19.9, -5.6) mg/day].Sirolimus might be effective and tolerated in SLE. The role of sirolimus in LN requires further study.CONCLUSIONSirolimus might be effective and tolerated in SLE. The role of sirolimus in LN requires further study.
Objective: To provide real-world data and summarize current clinical evidence on the efficacy and safety of sirolimus in active systemic lupus erythematosus (SLE) patients. Methods: This was a prospective real-world clinical study. Included SLE patients should have Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) ⩾ 2. They were treated with sirolimus and followed up regularly. The SLEDAI-2K, Physician Global Assessment (PGA), serological activity indices, and remission of organ manifestations were evaluated. We also performed a meta-analysis to integrate current evidence of sirolimus in SLE. Results: A total of 49 patients were included in the final analysis. After treatment, the SLEDAI-2K (6.2 ± 3.1 versus 4.0 ± 3.4, p = 0.001) decreased significantly, and the prednisone dosage was tapered successfully (9.9 ± 8.8 mg/day versus 5.9 ± 4.0 mg/day, p = 0.002). Serological activity indices also improved [complement 3 (C3): 0.690 ± 0.209 g/l versus 0.884 ± 0.219 g/l, p < 0.001; complement 4: 0.105 ± 0.059 g/l versus 0.141 ± 0.069 g/l, p < 0.001; anti-dsDNA antibody, 200 ± 178 IU/ml versus 156 ± 163 IU/ml, p = 0.022]. The remission proportions of arthritis, skin rash, and thrombocytopenia were 100%, 88.8%, and 46.2%, respectively. A total of 41.2% of lupus nephritis (LN) patients achieved renal remission, but the average 24-h urine protein level was not significantly changed. Meta-analysis enrolled five studies with 149 patients included, and revealed similar results regarding the changes of SLEDAI-2K [−3.5 (−5.0, −2.1)], C3 [0.224 (0.136, 0.311) g/l] and daily dosage of prednisone [−12.7 (−19.9, −5.6) mg/day]. Conclusion: Sirolimus might be effective and tolerated in SLE. The role of sirolimus in LN requires further study.
Author Sun, Yiduo
Tian, Xinping
Li, Mengtao
Zeng, Xiaofeng
Wu, Chanyuan
Qian, Junyan
Peng, Liying
Wang, Qian
Hong, Ruping
Zhao, Jiuliang
Wang, Yanhong
Author_xml – sequence: 1
  givenname: Liying
  orcidid: 0000-0001-8447-8121
  surname: Peng
  fullname: Peng, Liying
  organization: Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Science, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science & Technology, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China
– sequence: 2
  givenname: Chanyuan
  orcidid: 0000-0003-2710-9359
  surname: Wu
  fullname: Wu, Chanyuan
  organization: Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Science, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science & Technology, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China
– sequence: 3
  givenname: Ruping
  surname: Hong
  fullname: Hong, Ruping
  organization: Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Science, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science & Technology, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China
– sequence: 4
  givenname: Yiduo
  surname: Sun
  fullname: Sun, Yiduo
  organization: Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Science, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science & Technology, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China
– sequence: 5
  givenname: Junyan
  surname: Qian
  fullname: Qian, Junyan
  organization: Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Science, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science & Technology, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China
– sequence: 6
  givenname: Jiuliang
  surname: Zhao
  fullname: Zhao, Jiuliang
  organization: Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Science, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science & Technology, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China
– sequence: 7
  givenname: Qian
  surname: Wang
  fullname: Wang, Qian
  organization: Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Science, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science & Technology, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China
– sequence: 8
  givenname: Xinping
  surname: Tian
  fullname: Tian, Xinping
  organization: Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Science, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science & Technology, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China
– sequence: 9
  givenname: Yanhong
  surname: Wang
  fullname: Wang, Yanhong
  organization: Department of Epidemiology and Bio-statistics (YW), Institute of Basic Medical Science, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China
– sequence: 10
  givenname: Mengtao
  orcidid: 0000-0003-4252-2889
  surname: Li
  fullname: Li, Mengtao
  email: mengtao.li@cstar.org.cn
  organization: Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, No.1 Shuai fu yuan, East City, Beijing 100730, China
– sequence: 11
  givenname: Xiaofeng
  surname: Zeng
  fullname: Zeng, Xiaofeng
  email: zengxfpumc@163.com
  organization: Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Science, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science & Technology, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, No. 1 Shuaifuyuan, Beijing 100730, China
BackLink https://www.ncbi.nlm.nih.gov/pubmed/32973935$$D View this record in MEDLINE/PubMed
BookMark eNp9kkuLFDEURgsZcR66dyUFbtyUppLKy4UgjTMODLhRmF2Rx01PmlSlTVJK_Xurp8fWadDVDTfnO9w8zquTMY5QVS9b9LZtOX_Xcio5RrcYSUoIYU-qs12r4bgVJ4c1uj2tznPeIMQkku2z6pRgyYkk9KyKq-BHb1SowbmlmrlWo62zclDmOro6-xSDH6Zc-7HOcy4weFOHabt0IM3lDgZVYp7y-1rVCVRofsYUFkOZ7N41QFGNGlWYs8_Pq6dOhQwvHupF9e3y09fV5-bmy9X16uNNYygWpSGUU-cISGGNZMDBOmmdpUhrrpkiLbPIacqcXQAiHEiNDCZcdA4rLAS5qK73XhvVpt8mP6g091H5_r4R07pXqXgToHegkdWtFsBwRy1oLhRHhCujmdRgF9eHvWs76QGsgbEkFR5JH--M_q5fxx897yTBtF0Ebx4EKX6fIJd-8NlACGqEOOUedx1jDGNKF_T1EbqJU1ou755qRcewYAv16u-JDqP8ftcFQHvApJhzAndAWtTvvk5__HWWCDuKGF9U8XF3Jh_-F2z2wazW8Gfcf_K_AC3u10Q
CitedBy_id crossref_primary_10_1016_j_autrev_2022_103132
crossref_primary_10_3389_fimmu_2023_1321228
crossref_primary_10_1016_j_clim_2024_110224
crossref_primary_10_1080_17512433_2022_2138340
crossref_primary_10_1177_1759720X221079253
crossref_primary_10_1515_mr_2023_0032
crossref_primary_10_1007_s00296_023_05363_w
crossref_primary_10_1016_j_jaut_2022_102892
crossref_primary_10_1093_mrcr_rxac033
crossref_primary_10_1093_rheumatology_kead160
crossref_primary_10_1136_lupus_2021_000617
crossref_primary_10_1172_jci_insight_160377
crossref_primary_10_4049_jimmunol_2400127
crossref_primary_10_1097_MD_0000000000031551
crossref_primary_10_1016_j_intimp_2024_113722
crossref_primary_10_1016_j_jaci_2022_08_003
crossref_primary_10_3389_fphar_2023_1194816
crossref_primary_10_1155_2021_3746335
crossref_primary_10_1016_j_clim_2023_109288
crossref_primary_10_1093_stcltm_szae044
crossref_primary_10_1016_j_jaut_2024_103335
crossref_primary_10_3390_ph15080912
crossref_primary_10_1111_jcpt_13778
crossref_primary_10_1016_j_clim_2021_108781
crossref_primary_10_2147_RRU_S385836
crossref_primary_10_1016_j_intimp_2024_113916
crossref_primary_10_3390_diseases12090226
Cites_doi 10.1177/0961203307084712
10.1093/ndt/gfn216
10.1136/annrheumdis-2017-211631
10.1097/TP.0b013e31824bbd01
10.1155/2013/548085
10.1097/TP.0b013e318211d342
10.1016/j.transproceed.2010.12.039
10.1016/S0140-6736(10)61354-2
10.1136/bmj.g6679
10.1136/annrheumdis-2013-203794
10.4049/jimmunol.175.12.8392
10.1007/s11926-016-0622-8
10.1182/blood-2008-07-162503
10.1002/ajh.25119
10.1002/art.1780370219
10.1111/ajt.12543
10.1038/nrrheum.2015.172
10.1177/0961203319877239
10.1111/j.1600-6143.2007.02142.x
10.1111/j.1600-6143.2012.04334.x
10.1002/art.22085
10.1016/j.immuni.2015.08.017
10.1002/art.39791
10.1136/annrheumdis-2019-215039
10.1136/ard.2010.129320
10.1136/annrheumdis-2018-213028
10.1002/art.40380
10.2215/CJN.03751106
10.1172/JCI73411
10.1002/acr.21664
10.3899/jrheum.180507
10.3389/fphar.2019.00082
10.1681/ASN.2005090993
10.1038/nrrheum.2010.60
10.1111/j.1440-1797.2012.01646.x
10.1093/ndt/gfq496
10.1177/0961203307081401
10.1016/S0140-6736(18)30485-9
10.1002/jcp.25913
10.1038/s41584-019-0356-x
10.1016/j.jaut.2006.06.005
10.1182/blood-2015-07-657981
10.3109/09537104.2012.748188
10.1097/MPH.0000000000000818
10.1016/j.semarthrit.2019.09.022.
10.4049/jimmunol.1301005
10.1371/journal.pone.0050909
10.4049/jimmunol.1301859
10.1038/nrrheum.2015.178
ContentType Journal Article
Copyright The Author(s), 2020
The Author(s), 2020.
The Author(s), 2020. This work is licensed under the Creative Commons Attribution – Non-Commercial License https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s), 2020 2020 SAGE Publications Ltd unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses
Copyright_xml – notice: The Author(s), 2020
– notice: The Author(s), 2020.
– notice: The Author(s), 2020. This work is licensed under the Creative Commons Attribution – Non-Commercial License https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s), 2020 2020 SAGE Publications Ltd unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses
DBID AFRWT
AAYXX
CITATION
NPM
3V.
7RV
7X7
7XB
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
KB0
M0S
NAPCQ
PHGZM
PHGZT
PIMPY
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1177/1759720X20953336
DatabaseName Sage Journals GOLD Open Access 2024
CrossRef
PubMed
ProQuest Central (Corporate)
Nursing & Allied Health Database
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
ProQuest Health & Medical Collection
Nursing & Allied Health Premium
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
ProQuest Central (New)
ProQuest One Academic Eastern Edition
ProQuest Nursing & Allied Health Source
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
ProQuest Nursing & Allied Health Source (Alumni)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList PubMed

Publicly Available Content Database
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: AFRWT
  name: Sage Journals GOLD Open Access 2024
  url: http://journals.sagepub.com/
  sourceTypes: Publisher
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1759-7218
ExternalDocumentID oai_doaj_org_article_feb0db1b8e6245deb78a7037acb69bed
PMC7493251
32973935
10_1177_1759720X20953336
10.1177_1759720X20953336
Genre Journal Article
GrantInformation_xml – fundername: Chinese National High Technology Research and Development Program
  grantid: 2012AA02A513
– fundername: national key research and development program of china stem cell and translational research
  grantid: 2008BAI59B02
  funderid: https://doi.org/10.13039/501100013290
– fundername: Chinese National Key Research and Development Program
  grantid: 2017YFC0907600
– fundername: ;
  grantid: 2017YFC0907600
– fundername: ;
  grantid: 2008BAI59B02
– fundername: ;
  grantid: 2012AA02A513
GroupedDBID ---
-TM
.WF
01A
0R~
4.4
53G
54M
7RV
7X7
8FI
8FJ
AABMB
AADUE
AAKDD
AAQDB
AARDL
AARIX
AASGM
ABAWP
ABEIX
ABFWQ
ABJIS
ABKRH
ABQXT
ABRHV
ABUWG
ABVFX
ACARO
ACDSZ
ACDXX
ACGFS
ACOFE
ACROE
ACRPL
ADBBV
ADEBD
ADNMO
ADOGD
ADYCS
ADZZY
AEFTW
AEQLS
AERKM
AEUHG
AEWDL
AEXNY
AFCOW
AFEET
AFKRA
AFKRG
AFRWT
AFUIA
AFWMB
AGNHF
AGQPQ
AHHFK
AJUZI
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
ARTOV
ASPBG
AUTPY
AVWKF
AYAKG
AZFZN
B8M
BAWUL
BDDNI
BENPR
BKEYQ
BKSCU
BPHCQ
BSEHC
BVXVI
CAG
CCPQU
CDWPY
CFDXU
COF
DC-
DC.
DIK
DOPDO
EBS
EJD
EMOBN
F5P
FEDTE
FYUFA
GROUPED_DOAJ
GROUPED_SAGE_PREMIER_JOURNAL_COLLECTION
GX1
H13
HF~
HMCUK
HVGLF
HYE
HZ~
J8X
K.F
N9A
NAPCQ
O9-
OK1
P.B
PHGZM
PHGZT
PIMPY
PQQKQ
ROL
RPM
S01
SAUOL
SCDPB
SCNPE
SFC
UKHRP
ZONMY
ZPPRI
ZRKOI
ZSSAH
AAYXX
ACHEB
CITATION
31X
AADTT
AATBZ
ACGZU
ACSBE
ACSIQ
ACTQU
ACUIR
AEUIJ
AEWHI
B8Z
DV7
M4V
NPM
3V.
7XB
8FK
AZQEC
DWQXO
K9.
PKEHL
PPXIY
PQEST
PQUKI
PRINS
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c528t-3575ff3e98dc96e7edf9dfd50bb7b6a316d0fb56fd8dc38fe9b0c23784f2a2883
IEDL.DBID 7X7
ISSN 1759-720X
IngestDate Wed Aug 27 01:26:56 EDT 2025
Thu Aug 21 13:39:23 EDT 2025
Thu Jul 10 23:28:18 EDT 2025
Fri Jul 25 20:14:28 EDT 2025
Wed Feb 19 02:27:09 EST 2025
Thu Apr 24 23:11:07 EDT 2025
Tue Jul 01 05:25:55 EDT 2025
Tue Jun 17 22:29:34 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords mTOR inhibitor
treatment
lupus nephritis
systemic lupus erythematosus
thrombocytopenia
sirolimus
Language English
License This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
The Author(s), 2020.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c528t-3575ff3e98dc96e7edf9dfd50bb7b6a316d0fb56fd8dc38fe9b0c23784f2a2883
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
content type line 14
ObjectType-Feature-3
ObjectType-Evidence Based Healthcare-1
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
Liying Peng, Chanyuan Wu and Ruping Hong contributed equally to this article.
ORCID 0000-0001-8447-8121
0000-0003-2710-9359
0000-0003-4252-2889
OpenAccessLink https://www.proquest.com/docview/2441846286?pq-origsite=%requestingapplication%
PMID 32973935
PQID 2441846286
PQPubID 4450846
ParticipantIDs doaj_primary_oai_doaj_org_article_feb0db1b8e6245deb78a7037acb69bed
pubmedcentral_primary_oai_pubmedcentral_nih_gov_7493251
proquest_miscellaneous_2446662255
proquest_journals_2441846286
pubmed_primary_32973935
crossref_primary_10_1177_1759720X20953336
crossref_citationtrail_10_1177_1759720X20953336
sage_journals_10_1177_1759720X20953336
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2020-00-00
PublicationDateYYYYMMDD 2020-01-01
PublicationDate_xml – year: 2020
  text: 2020-00-00
PublicationDecade 2020
PublicationPlace London, England
PublicationPlace_xml – name: London, England
– name: England
– name: London
– name: Sage UK: London, England
PublicationTitle Therapeutic advances in musculoskeletal disease
PublicationTitleAlternate Ther Adv Musculoskelet Dis
PublicationYear 2020
Publisher SAGE Publications
SAGE PUBLICATIONS, INC
SAGE Publishing
Publisher_xml – name: SAGE Publications
– name: SAGE PUBLICATIONS, INC
– name: SAGE Publishing
References Chu, Zhao, Zhang 2019; 28
Qi, Zhou, Cheng 2018; 77
Wu, Fu, Guo 2019; 78
Stylianou, Petrakis, Mavroeidi 2011; 26
Sharabi, Tsokos 2020; 16
Li, Wang, Dai 2013; 2013
Ray, Staron, Shyer 2015; 43
Miyara, Amoura, Parizot 2005; 175
Crispin, Kyttaris, Terhorst 2010; 6
Asrani, Wiesner, Trotter 2014; 14
Tsokos 2016; 12
Kato, Perl 2018; 70
Campistol, Eris, Oberbauer 2006; 17
Ramos-Barron, Pinera-Haces, Gomez-Alamillo 2007; 16
Lui, Tsang, Chan 2008; 23
Wadei, Zaky, Keaveny 2012; 93
Teke, Gunduz, Akay 2013; 24
Ji, Zhan, Hua 2012; 7
Wiseman, McCague, Kim 2013; 13
Zeng, Qin, Zhang 2018; 233
Lai, Borsuk, Shadakshari 2013; 191
Letavernier, Bruneval, Mandet 2007; 2
Yap, Tang, Chan 2018; 45
He, Ma, Ren 2019
Perl 2016; 12
Koga, Hedrich, Mizui 2014; 124
Zhang, Bae, Bass 2018; 77
Oaks, Winans, Caza 2016; 68
Bride, Vincent, Smith-Whitley 2016; 127
Sinclair, Appel, Dooley 2007; 16
Kato, Perl 2014; 192
Alvarado-Sanchez, Hernandez-Castro, Portales-Perez 2006; 27
Stallone, Infante, Pontrelli 2011; 91
Jasinski, Weinblatt, Glasser 2017; 39
Eriksson, Wallin, Sjowall 2019; 10
Vizza, Perri, Toteda 2018; 14
Navarra, Guzman, Gallacher 2011; 377
Caza, Fernandez, Talaber 2014; 73
Yap, Ma, Tang 2012; 17
Warner, Adams, Sehgal 1994; 37
van Bavel, Dieker, Kroeze 2011; 70
Aliabadi, Pohanka, Seebacher 2008; 8
Oaks, Winans, Huang 2016; 18
Lai, Kelly, Winans 2018; 391
Hahn, McMahon, Wilkinson 2012; 64
Fernandez, Bonilla, Mirza 2006; 54
Miano, Rotulo, Palmisani 2018; 93
Rodeghiero, Stasi, Gernsheimer 2009; 113
Branco, Cavadas, Osorio 2011; 43
Knoll, Kokolo, Mallick 2014; 349
bibr47-1759720X20953336
bibr20-1759720X20953336
bibr39-1759720X20953336
bibr13-1759720X20953336
bibr8-1759720X20953336
bibr11-1759720X20953336
bibr48-1759720X20953336
bibr9-1759720X20953336
bibr14-1759720X20953336
bibr10-1759720X20953336
bibr36-1759720X20953336
bibr23-1759720X20953336
bibr49-1759720X20953336
bibr15-1759720X20953336
bibr22-1759720X20953336
bibr2-1759720X20953336
bibr28-1759720X20953336
bibr43-1759720X20953336
bibr30-1759720X20953336
bibr38-1759720X20953336
bibr25-1759720X20953336
bibr7-1759720X20953336
bibr12-1759720X20953336
bibr17-1759720X20953336
bibr50-1759720X20953336
bibr34-1759720X20953336
bibr33-1759720X20953336
bibr4-1759720X20953336
bibr41-1759720X20953336
bibr26-1759720X20953336
bibr32-1759720X20953336
bibr18-1759720X20953336
bibr35-1759720X20953336
bibr40-1759720X20953336
bibr5-1759720X20953336
bibr27-1759720X20953336
bibr31-1759720X20953336
bibr1-1759720X20953336
bibr44-1759720X20953336
Vizza D (bibr46-1759720X20953336) 2018; 14
bibr19-1759720X20953336
bibr45-1759720X20953336
bibr6-1759720X20953336
bibr24-1759720X20953336
bibr29-1759720X20953336
bibr37-1759720X20953336
bibr16-1759720X20953336
bibr21-1759720X20953336
bibr3-1759720X20953336
bibr42-1759720X20953336
References_xml – volume: 124
  start-page: 2234
  year: 2014
  end-page: 2245
  article-title: CaMK4-dependent activation of AKT/mTOR and CREM-alpha underlies autoimmunity-associated Th17 imbalance
  publication-title: J Clin Invest
– volume: 28
  start-page: 1397
  year: 2019
  end-page: 1406
  article-title: Restoring T-helper 17 cell/regulatory T-cell balance and decreasing disease activity by rapamycin and all-trans retinoic acid in patients with systemic lupus erythematosus
  publication-title: Lupus
– volume: 192
  start-page: 4134
  year: 2014
  end-page: 4144
  article-title: Mechanistic target of rapamycin complex 1 expands Th17 and IL-4+ CD4–CD8– double-negative T cells and contracts regulatory T cells in systemic lupus erythematosus
  publication-title: J Immunol
– volume: 127
  start-page: 17
  year: 2016
  end-page: 28
  article-title: Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial
  publication-title: Blood
– volume: 77
  start-page: 1799
  year: 2018
  end-page: 1809
  article-title: Increased autophagy is cytoprotective against podocyte injury induced by antibody and interferon-alpha in lupus nephritis
  publication-title: Ann Rheum Dis
– volume: 45
  start-page: 1663
  year: 2018
  end-page: 1670
  article-title: Longterm data on sirolimus treatment in patients with lupus nephritis
  publication-title: J Rheumatol
– volume: 64
  start-page: 797
  year: 2012
  end-page: 808
  article-title: American college of rheumatology guidelines for screening, treatment, and management of lupus nephritis
  publication-title: Arthritis Care Res (Hoboken)
– volume: 233
  start-page: 516
  year: 2018
  end-page: 529
  article-title: Rapamycin attenuates BAFF-extended proliferation and survival via disruption of mTORC1/2 signaling in normal and neoplastic B-lymphoid cells
  publication-title: J Cell Physiol
– volume: 391
  start-page: 1186
  year: 2018
  end-page: 1196
  article-title: Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial
  publication-title: Lancet
– volume: 93
  start-page: 1006
  year: 2012
  end-page: 1012
  article-title: Proteinuria following sirolimus conversion is associated with deterioration of kidney function in liver transplant recipients
  publication-title: Transplantation
– volume: 37
  start-page: 289
  year: 1994
  end-page: 297
  article-title: Rapamycin prolongs survival and arrests pathophysiologic changes in murine systemic lupus erythematosus
  publication-title: Arthritis Rheum
– volume: 70
  start-page: 427
  year: 2018
  end-page: 438
  article-title: Blockade of treg cell differentiation and function by the interleukin-21-mechanistic target of rapamycin axis via suppression of autophagy in patients with systemic lupus erythematosus
  publication-title: Arthritis Rheumatol
– volume: 2013
  start-page: 548085
  year: 2013
  article-title: Effects of rapamycin combined with low dose prednisone in patients with chronic immune thrombocytopenia
  publication-title: Clin Dev Immunol
– volume: 349
  start-page: g6679
  year: 2014
  article-title: Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data
  publication-title: BMJ
– volume: 17
  start-page: 676
  year: 2012
  end-page: 680
  article-title: Proliferation signal inhibitors in the treatment of lupus nephritis: preliminary experience
  publication-title: Nephrology (Carlton)
– volume: 43
  start-page: 690
  year: 2015
  end-page: 702
  article-title: The Interleukin-2-mTORc1 kinase axis defines the signaling, differentiation, and metabolism of T helper 1 and follicular B helper T cells
  publication-title: Immunity
– volume: 26
  start-page: 498
  year: 2011
  end-page: 508
  article-title: The PI3K/Akt/mTOR pathway is activated in murine lupus nephritis and downregulated by rapamycin
  publication-title: Nephrol Dial Transplant
– volume: 77
  start-page: 355
  year: 2018
  end-page: 363
  article-title: A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea
  publication-title: Ann Rheum Dis
– volume: 191
  start-page: 2236
  year: 2013
  end-page: 2246
  article-title: Mechanistic target of rapamycin activation triggers IL-4 production and necrotic death of double-negative T cells in patients with systemic lupus erythematosus
  publication-title: J Immunol
– volume: 18
  start-page: 73
  year: 2016
  article-title: Activation of the mechanistic target of rapamycin in SLE: explosion of evidence in the last five years
  publication-title: Curr Rheumatol Rep
– volume: 23
  start-page: 2768
  year: 2008
  end-page: 2776
  article-title: Rapamycin attenuates the severity of established nephritis in lupus-prone NZB/W F1 mice
  publication-title: Nephrol Dial Transplant
– year: 2019
  article-title: Advances in systemic lupus erythematosus pathogenesis via mTOR signaling pathway
  publication-title: Semin Arthritis Rheum
– volume: 54
  start-page: 2983
  year: 2006
  end-page: 2988
  article-title: Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus
  publication-title: Arthritis Rheum
– volume: 8
  start-page: 854
  year: 2008
  end-page: 861
  article-title: Development of proteinuria after switch to sirolimus-based immunosuppression in long-term cardiac transplant patients
  publication-title: Am J Transplant
– volume: 27
  start-page: 110
  year: 2006
  end-page: 118
  article-title: Regulatory T cells in patients with systemic lupus erythematosus
  publication-title: J Autoimmun
– volume: 377
  start-page: 721
  year: 2011
  end-page: 731
  article-title: Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial
  publication-title: Lancet
– volume: 12
  start-page: 169
  year: 2016
  end-page: 182
  article-title: Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases
  publication-title: Nat Rev Rheumatol
– volume: 7
  start-page: e50909
  year: 2012
  article-title: The ratio of Treg/Th17 cells correlates with the disease activity of primary immune thrombocytopenia
  publication-title: PLoS One
– volume: 70
  start-page: 201
  year: 2011
  end-page: 207
  article-title: Apoptosis-induced histone H3 methylation is targeted by autoantibodies in systemic lupus erythematosus
  publication-title: Ann Rheum Dis
– volume: 24
  start-page: 625
  year: 2013
  end-page: 631
  article-title: Abnormality of regulatory T-cells in remission and non-remission idiopathic thrombocytopaenic purpura patients
  publication-title: Platelets
– volume: 2
  start-page: 326
  year: 2007
  end-page: 333
  article-title: High sirolimus levels may induce focal segmental glomerulosclerosis de novo
  publication-title: Clin J Am Soc Nephrol
– volume: 91
  start-page: 997
  year: 2011
  end-page: 1004
  article-title: Sirolimus and proteinuria in renal transplant patients: evidence for a dose-dependent effect on slit diaphragm-associated proteins
  publication-title: Transplantation
– volume: 10
  start-page: 82
  year: 2019
  article-title: Clinical experience of sirolimus regarding efficacy and safety in systemic lupus erythematosus
  publication-title: Front Pharmacol
– volume: 175
  start-page: 8392
  year: 2005
  end-page: 8400
  article-title: Global natural regulatory T cell depletion in active systemic lupus erythematosus
  publication-title: J Immunol
– volume: 43
  start-page: 137
  year: 2011
  end-page: 141
  article-title: The incidence of cancer and potential role of sirolimus immunosuppression conversion on mortality among a single-center renal transplantation cohort of 1,816 patients
  publication-title: Transplant Proc
– volume: 16
  start-page: 972
  year: 2007
  end-page: 980
  article-title: Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled aspreva lupus management study (ALMS)
  publication-title: Lupus
– volume: 14
  start-page: 1028
  year: 2018
  end-page: 1042
  article-title: Rapamycin-induced autophagy protects proximal tubular renal cells against proteinuric damage through the transcriptional activation of the nerve growth factor receptor NGFR
  publication-title: Autophagy
– volume: 39
  start-page: 420
  year: 2017
  end-page: 424
  article-title: Sirolimus as an effective agent in the treatment of immune thrombocytopenia (ITP) and evans syndrome (ES): a single institution’s experience
  publication-title: J Pediatr Hematol Oncol
– volume: 6
  start-page: 317
  year: 2010
  end-page: 325
  article-title: T cells as therapeutic targets in SLE
  publication-title: Nat Rev Rheumatol
– volume: 78
  start-page: 1090
  year: 2019
  end-page: 1100
  article-title: Lupus-associated atypical memory B cells are mTORC1-hyperactivated and functionally dysregulated
  publication-title: Ann Rheum Dis
– volume: 113
  start-page: 2386
  year: 2009
  end-page: 2393
  article-title: Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group
  publication-title: Blood
– volume: 13
  start-page: 442
  year: 2013
  end-page: 449
  article-title: The effect of everolimus versus mycophenolate upon proteinuria following kidney transplant and relationship to graft outcomes
  publication-title: Am J Transplant
– volume: 68
  start-page: 2728
  year: 2016
  end-page: 2739
  article-title: Mitochondrial dysfunction in the liver and antiphospholipid antibody production precede disease onset and respond to rapamycin in lupus-prone mice
  publication-title: Arthritis Rheumatol
– volume: 16
  start-page: 775
  year: 2007
  end-page: 781
  article-title: Prevention of murine lupus disease in (NZBxNZW)F1 mice by sirolimus treatment
  publication-title: Lupus
– volume: 12
  start-page: 74
  year: 2016
  end-page: 76
  article-title: Systemic lupus erythematosus in 2015: cellular and metabolic requirements of effector T cells
  publication-title: Nat Rev Rheumatol
– volume: 14
  start-page: 356
  year: 2014
  end-page: 366
  article-title: De novo sirolimus and reduced-dose tacrolimus versus standard-dose tacrolimus after liver transplantation: the 2000-2003 phase II prospective randomized trial
  publication-title: Am J Transplant
– volume: 73
  start-page: 1888
  year: 2014
  end-page: 1897
  article-title: HRES-1/Rab4-mediated depletion of Drp1 impairs mitochondrial homeostasis and represents a target for treatment in SLE
  publication-title: Ann Rheum Dis
– volume: 17
  start-page: 581
  year: 2006
  end-page: 589
  article-title: Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation
  publication-title: J Am Soc Nephrol
– volume: 93
  start-page: E175
  year: 2018
  end-page: E177
  article-title: Sirolimus as a rescue therapy in children with immune thrombocytopenia refractory to mycophenolate mofetil
  publication-title: Am J Hematol
– volume: 16
  start-page: 100
  year: 2020
  end-page: 112
  article-title: T cell metabolism: new insights in systemic lupus erythematosus pathogenesis and therapy
  publication-title: Nat Rev Rheumatol
– ident: bibr12-1759720X20953336
  doi: 10.1177/0961203307084712
– ident: bibr30-1759720X20953336
  doi: 10.1093/ndt/gfn216
– ident: bibr1-1759720X20953336
  doi: 10.1136/annrheumdis-2017-211631
– ident: bibr47-1759720X20953336
  doi: 10.1097/TP.0b013e31824bbd01
– ident: bibr34-1759720X20953336
  doi: 10.1155/2013/548085
– ident: bibr44-1759720X20953336
  doi: 10.1097/TP.0b013e318211d342
– ident: bibr49-1759720X20953336
  doi: 10.1016/j.transproceed.2010.12.039
– ident: bibr2-1759720X20953336
  doi: 10.1016/S0140-6736(10)61354-2
– ident: bibr50-1759720X20953336
  doi: 10.1136/bmj.g6679
– ident: bibr32-1759720X20953336
  doi: 10.1136/annrheumdis-2013-203794
– ident: bibr23-1759720X20953336
  doi: 10.4049/jimmunol.175.12.8392
– ident: bibr4-1759720X20953336
  doi: 10.1007/s11926-016-0622-8
– ident: bibr11-1759720X20953336
  doi: 10.1182/blood-2008-07-162503
– ident: bibr36-1759720X20953336
  doi: 10.1002/ajh.25119
– ident: bibr39-1759720X20953336
  doi: 10.1002/art.1780370219
– ident: bibr41-1759720X20953336
  doi: 10.1111/ajt.12543
– ident: bibr26-1759720X20953336
  doi: 10.1038/nrrheum.2015.172
– ident: bibr13-1759720X20953336
  doi: 10.1177/0961203319877239
– ident: bibr40-1759720X20953336
  doi: 10.1111/j.1600-6143.2007.02142.x
– ident: bibr42-1759720X20953336
  doi: 10.1111/j.1600-6143.2012.04334.x
– ident: bibr5-1759720X20953336
  doi: 10.1002/art.22085
– ident: bibr14-1759720X20953336
  doi: 10.1016/j.immuni.2015.08.017
– ident: bibr27-1759720X20953336
  doi: 10.1002/art.39791
– ident: bibr19-1759720X20953336
  doi: 10.1136/annrheumdis-2019-215039
– ident: bibr22-1759720X20953336
  doi: 10.1136/ard.2010.129320
– volume: 14
  start-page: 1028
  year: 2018
  ident: bibr46-1759720X20953336
  publication-title: Autophagy
– ident: bibr45-1759720X20953336
  doi: 10.1136/annrheumdis-2018-213028
– ident: bibr20-1759720X20953336
  doi: 10.1002/art.40380
– ident: bibr43-1759720X20953336
  doi: 10.2215/CJN.03751106
– ident: bibr16-1759720X20953336
  doi: 10.1172/JCI73411
– ident: bibr10-1759720X20953336
  doi: 10.1002/acr.21664
– ident: bibr6-1759720X20953336
  doi: 10.3899/jrheum.180507
– ident: bibr9-1759720X20953336
  doi: 10.3389/fphar.2019.00082
– ident: bibr48-1759720X20953336
  doi: 10.1681/ASN.2005090993
– ident: bibr21-1759720X20953336
  doi: 10.1038/nrrheum.2010.60
– ident: bibr7-1759720X20953336
  doi: 10.1111/j.1440-1797.2012.01646.x
– ident: bibr29-1759720X20953336
  doi: 10.1093/ndt/gfq496
– ident: bibr31-1759720X20953336
  doi: 10.1177/0961203307081401
– ident: bibr8-1759720X20953336
  doi: 10.1016/S0140-6736(18)30485-9
– ident: bibr18-1759720X20953336
  doi: 10.1002/jcp.25913
– ident: bibr25-1759720X20953336
  doi: 10.1038/s41584-019-0356-x
– ident: bibr24-1759720X20953336
  doi: 10.1016/j.jaut.2006.06.005
– ident: bibr33-1759720X20953336
  doi: 10.1182/blood-2015-07-657981
– ident: bibr37-1759720X20953336
  doi: 10.3109/09537104.2012.748188
– ident: bibr35-1759720X20953336
  doi: 10.1097/MPH.0000000000000818
– ident: bibr3-1759720X20953336
  doi: 10.1016/j.semarthrit.2019.09.022.
– ident: bibr17-1759720X20953336
  doi: 10.4049/jimmunol.1301005
– ident: bibr38-1759720X20953336
  doi: 10.1371/journal.pone.0050909
– ident: bibr15-1759720X20953336
  doi: 10.4049/jimmunol.1301859
– ident: bibr28-1759720X20953336
  doi: 10.1038/nrrheum.2015.178
SSID ssj0069091
Score 2.3261158
Snippet Objective: To provide real-world data and summarize current clinical evidence on the efficacy and safety of sirolimus in active systemic lupus erythematosus...
To provide real-world data and summarize current clinical evidence on the efficacy and safety of sirolimus in active systemic lupus erythematosus (SLE)...
Objective: To provide real-world data and summarize current clinical evidence on the efficacy and safety of sirolimus in active systemic lupus erythematosus...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
sage
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1759720X20953336
SubjectTerms Effectiveness
Inhibitor drugs
Lupus
Meta-analysis
Original Research
Patient safety
Serology
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQD4gLojxTCjISQuJgrWMncdwbIKoKqZyotLfI9thipW1SNclh_z1jJ7vb5Xnhak-iyXjs-cZ2viHkrVNaaSgFc6A0KwA4q6WtmbKlVBww5kFMFC-_VhdXxZdlubxT6iveCZvogSfDLYK3HGxua1-JogRvVW3QS5VxttLWQ1x9MeZtk6lpDcaUT-f7Q8kFxkitBF-KyK4mEx3zPgglrv7fAcxf70neueyV4s_5I_JwBo70w6TwMbnn28fk_uV8NP6EdDPD55r6yAph3IaaFmhvgh82tAu0X8UCPddjT1ctnQicV46uxxts8bebib2168f-jBqKUHLNEpsqTQS06V3XfjDMzCwmT8nV-edvny7YXE2BuVLUA5MIzEKQXtfgdOWVh6AhQMmtVbYyMq-AB1tWAVBA1sFry52Qqi6CMLEm8TNy1Hatf0EoggYjgwtBFFWRa2WBC8fBA0p7pcuMLLbmbdxMNR4rXqybfGYX_3lAMvJ-98TNRLPxF9mPccR2cpEgOzWg2zSz2zT_cpuMnG7Hu5lnbd8g1MGEN_6sm5E3u26cb_EQxbS-G5MMZny4CuJXPp_cY6eJjIXAtMQedeA4B6oe9rSr74nTWxUIpMs8I--ii-1V-pMRTv6HEV6SByJuH6QdpVNyNNyO_hVirMG-TtPpB_X0JOo
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Sage Journals GOLD Open Access 2024
  dbid: AFRWT
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwELbKVkJcEG8CBRkJIXEwm9hJHHNBBbGqkMoBtWJvkZ9lpd2kapLD_ns8jrNlKSCu9sTxY2Y847G_Qei15oILU1CiDRckNyYlFVMV4apgPDV-zzPgKJ5-LU_O8y_LYnmAmuktTJzB7h1cq_I9CsoapBtOo-cxyDj3e57gNF1SQEtjrPww9Jt6PO2ekmpACYSnhw1EtjXch9yS6XXbLXRIeVnQGTo8Xnz7fjbpbu8qhhx70D6BH1wHNm_8c28jC3j_fzJSb961_OXCWNjDFvfQ3Wh84uORW-6jA9s8QLdPY3j9IWojSugaW0CWkHqLZWNwJ53tt7h1uFtBkp_N0OFVg0cQ6JXG6-HSl_iRjwiwbTd077HE3hxdk4DIigOIbWhrY3tJZERCeYTOF5_PPp2QmJGB6IJWPWHeuHOOWVEZLUrLrXHCOFOkSnFVSpaVJnWqKJ3xBKxyVqhUU8ar3FEJeY0fo1nTNvYpwt7wkMxp52he5pngyqRUp8YaT225KBI0n6a31hGuHLJmrOssIpT_viAJerv74nKE6vgH7UdYsR0dgGyHgvbqoo4yWzurUqMyVdmS5oWxilfSK0gutSqFsiZBR9N61xPf1t5c8k4zPPhN0KtdtZdZCMTIxrZDoPFeo9ekfpRPRvbY9YRBMjHBfA3fY5y9ru7XNKsfARec594YL7IEvQEWu-7S3ybh2f8SPkd3KBwzhJOnIzTrrwb7wttivXoZBegnuTIv-w
  priority: 102
  providerName: SAGE Publications
Title Clinical efficacy and safety of sirolimus in systemic lupus erythematosus: a real-world study and meta-analysis
URI https://journals.sagepub.com/doi/full/10.1177/1759720X20953336
https://www.ncbi.nlm.nih.gov/pubmed/32973935
https://www.proquest.com/docview/2441846286
https://www.proquest.com/docview/2446662255
https://pubmed.ncbi.nlm.nih.gov/PMC7493251
https://doaj.org/article/feb0db1b8e6245deb78a7037acb69bed
Volume 12
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9swEBdbC2MvY9_z1gUNxmAPIrZlW9ZeRjsayqBllJblzUg6qQukdhbbD_nvJ8mKs-yjT4bT2ci-k-5L_h1C7xXjjEOeEgWMkwwgJiWVJWEypywGa_PABYrnF8XZdfZ1ns9Dwq0Nxyq3e6LfqKFRLkc-tWbIBiPuR8rPq5_EdY1y1dXQQuM-OnTQZU6r2XwMuGzg5zvmWQvJCUvj-a5MOXU0R0od3hr1AM07s-TR-__lcv59cvK341_eIs0eo0fBlcTHg-yfoHu6fooenIdi-TPUBMzPJdYOJ0KoDRY14FYY3W1wY3C7cC17bvsWL2o8QDovFF72K0vR682A59q0ffsJC2ydyyXx-KrYQ9L6Z93qThARcE2eo-vZ6dWXMxL6KxCVp2VHqHXVjKGal6B4oZkGw8FAHkvJZCFoUkBsZF4YsAy0NJrLWKWUlZlJhetS_AId1E2tXyFs3QhBjTImzYos4UxCnKoYNFhuzXgeoen281YqgI-7HhjLKgl4438KJEIfxztWA_DGHbwnTmIjn4PM9oRmfVOFFVgZLWOQiSx1kWY5aMlKYbc7JpQsuNQQoaOtvKuwjttqp3URejcO2xXoyiqi1k3veWwMaPdF-5YvB_UYZ0JdazBO7QjbU5y9qe6P1IsfHuWbZda1zpMIfXAqtpvS_z7C67vn_wY9TF2qwGePjtBBt-71W-tPdXLiF80EHR7PLr9f2evJ6cW3y4nPTvwCu6QguQ
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLbGkIAXxHUUBhgJkHiwmthJHCMhxG3q2LqnTepb8BUqdUlpGqH-KX4jx06aUi5726t9Yjn28bn48n0IPddccGFSSrThgiTGRCRnKidcpYxHBnye8Yni-CQbnSWfJ-lkB_1cv4Xx1yrXNjEYalNpv0c-BDcEyYh_SPl2_p141ih_urqm0GjV4siufkDKVr85_Ajz-4LSg0-nH0akYxUgOqX5kjAIUJxjVuRGi8xya5wwzqSRUlxlksWZiZxKM2dAgOXOChVpynieOCo9Ny-0ewVdBccb-WSPT_oEDxLNwNAHHlkQTqPJ5lh06Mt8EfX4biwAQm_cYGAL-FeI-_dNzd-umwUPeHAL3exCV_yu1bXbaMeWd9C1cXc4fxdVHcboDFuPSyH1CsvS4Fo6u1zhyuF66imCzpsaT0vcQkhPNZ41cyixi1WLH1vVTf0aSwzB7IwEPFccIHBDW-d2KYnscFTuobNLGfn7aLesSvsAYQhbJHPaOZpkSSy4MhHVkbEGpC0X6QAN18Nb6A7s3HNuzIq4wzf_c0IG6FX_xbwF-rhA9r2fsV7OQ3SHgmrxtehWfOGsioyKVW4zmqTGKp5LMK9capUJZc0A7a_nu-jsRl1stHyAnvXVsOL9MY4sbdUEGcg5wQ7DX-616tH3hHkqMsGghm8pzlZXt2vK6beAKs4TCOXTeIBeehXbdOl_g_Dw4v4_RddHp-Pj4vjw5OgRukH9NkXYudpHu8tFYx9DLLdUT8ICwujLZa_YX8zeW1Q
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lj9MwELagK624IN5bWMBICImDaWInccxteVTLY1cI7YreIj-hUjepmuTQf8_YcbuUBcQ1HluOHzPfeOxvEHquueDC5JRowwXJjElIyVRJuMoZTwzYPOMdxZPT4vg8-zjLZ_Fujn8LE0ewfeWvVUGPgrL2u3tp3CTGGCdg8gSnyYx6sjTGiutoL8vAxxuhvaPp129nG1UMnl9Imeflia9wGae80saOXQr0_X_CnFevTv5y_yuYpOktdDNiSXw0TP5tdM3Wd9D-SYyW30VNJP1cYOuJIqReY1kb3EpnuzVuHG7nPmfPRd_ieY0HTue5xot-CV_saj0QujZt377GEgO6XJBAsIoDJ21o68J2kshIbHIPnU_fn709JjHBAtE5LTvCAKs5x6wojRaF5dY4YZzJE6W4KiRLC5M4lRfOgAArnRUq0ZTxMnNU-jTF99Gobmp7gDDgCMmcdo5mRZYKrkxCdWKsAWnLRT5Gk83wVjqyj_skGIsqjYTjv0_IGL3c1lgOzBv_kH3jZ2wr5zmzw4dm9b2KW7ByViVGpaq0Bc1yYxUvJeg7LrUqhLJmjA43811tlmEF6Ad8YP9-d4yebYthC_q4iqxt0wcZcAJBMcJfPhiWx7YnzOcGEwxK-M7C2enqbkk9_xFovnkG2DpPx-iFX2KXXfrbIDz8X8GnaP_Lu2n1-cPpp0foBvUHCOFM6RCNulVvHwPK6tSTuJd-AmM-HnQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinical+efficacy+and+safety+of+sirolimus+in+systemic+lupus+erythematosus%3A+a+real-world+study+and+meta-analysis&rft.jtitle=Therapeutic+advances+in+musculoskeletal+disease&rft.au=Peng+Liying&rft.au=Wu+Chanyuan&rft.au=Hong+Ruping&rft.au=Sun+Yiduo&rft.date=2020&rft.pub=SAGE+PUBLICATIONS%2C+INC&rft.issn=1759-720X&rft.eissn=1759-7218&rft.volume=12&rft_id=info:doi/10.1177%2F1759720X20953336
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1759-720X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1759-720X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1759-720X&client=summon